Mabion S.A.

Equities

MAB

PLMBION00016

Biotechnology & Medical Research

Delayed Warsaw S.E. Other stock markets 11:55:56 2024-04-24 am EDT			5-day change	1st Jan Change
16.64 ^PLN	-1.77%		-5.45%	-8.32%

Apr. 16	Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

AMATHUS 3 FIZ fund of AMATHUS Towarzystwo Funduszy Inwestycyjnych S.A. acquired additional 4.17% stake in Mabion SA.

August 17, 2015 at 12:00 am EDT

AMATHUS Towarzystwo Funduszy Inwestycyjnych S.A. acquired additional 4.17% stake in Mabion SA (WSE:MAB) on August 17, 2015.

AMATHUS Towarzystwo Funduszy Inwestycyjnych S.A. completed the acquisition of additional 4.17% stake in Mabion SA (WSE:MAB) on August 17, 2015.

Latest news about Mabion S.A.

Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Mabion S.A.(WSE:MAB) dropped from S&P Global BMI Index	23-09-18	CI
Mabion S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-12	CI
Ryvu and TIM to enter Warsaw's mWIG40 index	23-08-31	RE
Mabion S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-18	CI
Mabion Announces Extension of Deal with Novavax	23-04-06	CI
Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
Mabion S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-09-29	CI
Mabion S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-27	CI
Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-21	CI
Mabion S.A. Auditor Raises 'Going Concern' Doubt	22-04-20	CI
Mabion S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Mabion S.A.(WSE:MAB) added to S&P Global BMI Index	21-09-20	CI
Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-09-16	CI
Mabion S A : Big pharma and private equity seek healthy returns in Europe's east	21-05-20	RE
MABION Announces Executive Changes	21-05-14	CI
Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Mabion S.A. Auditor Raises 'Going Concern' Doubt	21-04-29	CI
Stoxx Europe 600 : Polish Biotech Mabion Enters Deal To Manufacture Novavax COVID-19 Jab	21-03-04	MT
Mabion Biotech Signs Deal with Novavax on Covid-19 Vaccine Technology Transfer	21-03-03	CI
Mabion S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-23	CI
Mabion S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-09-22	CI
Mabion S.A. announced that it expects to receive PLN 1.563755 million in funding	20-05-17	CI

Chart Mabion S.A.

Duration

Period

More charts

Company Profile

Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mabion S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

16.64 PLN

Average target price

16.17 PLN

Spread / Average Target

-2.84%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MABION S.A.	-8.32%	66.36M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	104B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.42B
ARGENX SE	+1.86%	22.2B
BIONTECH SE	-16.53%	21.23B
GENMAB A/S	-8.49%	18.33B
WUXI APPTEC CO., LTD.	-42.33%	16.35B
BEIGENE, LTD.	-20.09%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	13.98B
SAREPTA THERAPEUTICS, INC.	+28.85%	11.66B

Bio Therapeutic Drugs